Sunitinib treatment of unresectable malignant pheochromocytoma and paraganglioma
Phase of Trial: Phase I
Latest Information Update: 03 May 2018
At a glance
- Drugs Sunitinib (Primary)
- Indications Paraganglioma; Phaeochromocytoma
- Focus Therapeutic Use
- 01 May 2018 Status changed from recruiting to completed.
- 01 Dec 2011 Status changed from not yet recruiting to recruiting according to University Hospital Medical Information Network - Japan record.
- 25 Oct 2011 New trial record